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Bridge to Transplantation with a Left Ventricular Assist Device
Jae  Jun  Jung,  M.D.,  Kiick  Sung,  M.D.,  Dong  Seop  Jeong,  M.D,  Wook  Sung  Kim,  M.D., 
Young  Tak  Lee,  M.D.,  Pyo  Won  Park,  M.D.
A 61-year-old female patient was diagnosed with dilated cardiomyopathy with severe left ventricle dysfunction. Two 
days after admission, continuous renal replacement therapy was performed due to oliguria and lactic acidosis. On 
the fifth day, an intra-aortic balloon pump was inserted due to low cardiac output syndrome. Beginning 4 days af-
ter admission, she was supported for 15 days thereafter with an extracorporeal left ventricular assist device (LVAD) 
because of heart failure with multi-organ failure. A heart transplant was performed while the patient was stabilized 
with the LVAD. She developed several complications after the surgery, such as cytomegalovirus pneumonia, pulmo-
nary tuberculosis, wound dehiscence, and H1N1 infection. On postoperative day 19, she was discharged from the 
hospital with close follow-up and treatment for infection. She received follow-up care for 10 months without any im-
mune rejection reaction.
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CASE REPORT
A  61-year-old  woman  presented  to  the  hospital  with  or-
thopnea  as  her  chief  complaint.  Symptoms  were  first  noticed 
three months prior to the hospital visit. Seven weeks prior to 
the  visit,  she  went  to  a  nearby  hospital  complaining  of  even 
more  severe  orthopnea.  An  echocardiogram  showed  that  her 
left  ventricular  ejection  fraction  (LVEF)  was  10%;  she  was 
then  admitted  to  our  hospital  for  a  more  detailed  diagnosis 
and  heart  transplantation.
In 2004, although she was diagnosed with atrial fibrillation 
and  warfarin was  prescribed, she did not  take warfarin. After 
diagnosis, she was closely observed, and an echocardiography 
was  performed  in  2009.  Because  her  LVEF  was  measured  at 
20%,  an  implantable  cardioverter-defibrillator  was  inserted  to 
prevent  sudden  cardiac  arrest.
A n  e x a m i n a t i o n  o f  h e r  f a m i l y  h i s t o r y  r e v e a l e d  t h a t  h e r  f a -
ther  had  died  when  he  was  approximately  40  years  of  age, 
and her younger brother had also died suddenly for unknown 
reasons.
On  admission,  transthoracic  echocardiography  showed  di-
lated  cardiomyopathy  with  left  ventricle  systolic  dysfunction. 
This  was  combined  with  right  ventricle  dilation  with  systolic 
dysfunction.  The  LVEF  was  measured  at  only  10%.  Severe 
cardiomegaly  was  found  on  the  chest  X-ray  (Fig.  1).  B-type 
natriuretic  peptide  was  elevated  to  35,000  pg/mL.
During  the  second  day  of  hospitalization,  continuous  renal 
replacement  therapy  was  performed  because  of  oliguria  and Extracorporeal Left Ventricular Assist Device
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Fig. 1. (A) Preoperative chest X-ray 
of the patient. The chest X-ray shows
severe cardiomegaly and an implant-
able cardioverter-defibrillator. (B) Left 
ventricular assist device support state.
Fig. 2. Intraoperative view. A 22 Fr straight cannula was inserted 
into the aorta, and a 30 Fr angled cannula was inserted into the 
left atrium.
l a c t i c  a c i d o s i s .  O n  t h e  f i f t h  d a y  o f  h o s p i t a l i z a t i o n ,  t h e  t o t a l  
bilirubin,  aspartate  aminotransferase  (AST),  and  alanine  ami-
notransferase  (ALT)  were  5.6,  1,032,  and  534  U/L,  respec-
tively.  Those  findings  were  thought  to  be  the  results  of  liver 
congestion  caused  by  heart  failure.  An  intra-aortic  balloon 
pump was inserted to improve low cardiac output. During the 
ninth day of hospitalization, respiratory acidosis occurred as a 
result  of  respiratory  difficulty.  Subsequently,  the  patient’s 
heart  rate  slowed  down,  finally  resulting  in  cardiac  arrest. 
The  patient  was  revived  after  11  minutes  of  cardiopulmonary 
cerebral  resuscitation.
We concluded that heart transplantation was the only viable 
treatment and decided to insert a left ventricular assist device 
(LVAD)  as  a  bridge  to  heart  transplantation.
In  the  operating  room,  a  median  sternotomy  was  perfor-
med.  A  22  Fr  straight  cannula  (Edwards  Life  Sciences 
Research  Medical  RMI  cannula,  Irvine,  CA,  USA)  was  in-
serted  into  the  aorta,  and  a  30  Fr  angled  cannula  (Edwards 
Lifesciences Research Medical RMI cannula) was inserted in-
to  the  left  atrium,  and  a  pulmonary  artery  cannula  was  in-
serted  into  the  main  pulmonary  artery  to  monitor  pulmonary 
a r t e r i a l  p r e s s u r e  ( F i g .  2 ) .  A  J ostra  pump  (Maquet  Cardiopul-
monary;  AG,  Hirrlingen,  Germany)  was  also  used.  The  can-
nula  exited  through  the  anterior  chest  wall.  The  sternum  was 
closed  and  the  skin  was  closed  layer  by  layer.  The  pump’s 
speed  was  between  2,800  and  3,200  revolutions  per  minute, 
and  its  flow  was  2.6  to  3.2  L/min.  Anticoagulation  therapy 
was performed using heparin to maintain an activated clotting 
time  around  180  to  220  seconds,  and  after  LVAD  insertion, 
the  patient’s  vital  signs  stabilized.  By  continuously  infusing 
diuretics, the urine output was also stabilized between 100 to 
300  mL/hr. 
Also, inhaled nitric oxide (NO) was started in the intensive 
care  unit  for  right  ventricular  dysfunction.  The  maximal  dose 
of  inhaled  NO  was  20  ppm.
The  AST,  ALT,  and  creatinine  levels,  which  indicate 
end-organ  function,  started  to  decrease  5  days  after  the 
LVAD insertion. The appropriate amount of urine output was 
also  maintained  without  diuretics  5  days  after  the  LVAD 
insertion.
O n  t h e  t w e n t i e t h  d a y  o f  h o s p i t a l i z a t i o n ,  t h e  t o t a l  b i l i r u b i n  
AST,  and  ALT  were  measured  at  5.5,  47,  and  19  U/L, 
respectively.  On  the  twenty-fourth  day  of  hospitalization,  the Jae Jun Jung, et al
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heart  transplantation  was  performed  while  stabilizing  the  pa-
tient  with  LVAD.  Redo-sternotomy  was  performed.  There 
was  a  hematoma  around  the  pericardium.  Cannulation  was 
performed at the distal aorta, inferior vena cava, and superior 
vena  cava  for  cardiopulmonary  bypass  (CPB).  After  starting 
the CPB, we decreased the LVAD flow gradually and finally 
removed the LVAD with its cannulae. A thrombus was found 
at  the  point  where  the  pulmonary  artery  catheter  was  located 
for  the  LVAD.  The  remaining  cannulae  did  not  reveal  any 
unusual  findings.  The  heart  size  was  16×10×9  cm.
All  four  chambers  were  dilated,  and  the  septum  and  the 
myocardial  wall  were  thin.  Before  surgery,  basiliximab  was 
used  as  an  immunosuppressant,  and  vancomycin  and  mer-
openem  were  used  as  antibiotics.  After  surgery,  methyl-pre-
dnisolone  (Solu-Medrol;  Pharmacia  Upjohn,  Peapack,  NJ, 
USA),  tacrolimus,  and  basiliximab  were  used.  She  developed 
several complications after the surgery, including cytomegalo-
virus  pneumonia,  pulmonary  tuberculosis,  wound  dehiscence, 
and  H1N1  infection.
On  the  ninetieth  postoperative  day,  she  was  discharged 
from  the  hospital  with  close  follow-up  and  treatment  for 
infection. Currently, she frequently visits the hospital for out-
patient  treatment.
DISCUSSION
A heart transplantation is the only available treatment when 
advanced  ischemic  heart  failure  occurs  and  dilated  cardiomy-
opathy  is  unresponsive  to  medical  treatment.  However,  the 
number of  donor hearts  available for transplantation  for these 
patients is insufficient [1]. Some patients can die of multi-or-
gan failure while they are waiting for heart donors. LVAD is 
known  to  be  a  good  alternative  as  a  bridge  for  heart 
transplantation.
Since  the  beginning  of  the  artificial  heart  program  at  the 
National  Institute  of  Health  in  1964,  diverse  circulatory-sup-
port  devices  have  been  developed  for  short-term  use  in  pa-
tients with advanced heart failure [2]. A ventricular assist de-
vice  (VAD)  was  successfully  applied  in  1971  by  DeBakey 
[3];  it  then  began  to  be  used  as  a  bridge  to  transplantation, 
bridge to recovery, and bridge to destination therapy. The ad-
vantages  of  VAD  are  increasing  the  functional  status  and 
quality  of  life,  but  possible  complications  may  develop,  such 
as  thromboembolism,  hemorrhage,  right  heart  failure,  and 
stroke. If early insertion is performed before multi-organ fail-
ure,  it  may  decrease  the  risk  of  complications  and  increase 
the  survival  rate  [1].
In our  case,  the  patient  experienced  advanced  heart  failure, 
and  her  level  of  LVEF  was  at  10%  as  a  result  of  dilated 
cardiomyopathy.  Acute  kidney  injury  occurred  before  the 
VAD insertion, in addition to liver injury due to heart failure. 
Subsequently,  cardiac  arrest  occurred  and  multi-organ  failure 
commenced due to pulmonary edema and respiratory acidosis. 
We  were  worried  about  the  application  of  extracorporeal 
membrane oxygenation (ECMO) or VAD as a bridge to heart 
transplantation.  From  past  experience,  ECMO  had  not  im-
proved  measures  of  end-organ  function,  such  as  AST,  ALT, 
and creatinine levels, which are indicators of liver and kidney 
function.  However,  a  VAD  improved  end-organ  function.  A 
VAD  can  also  supply  effective  hemodynamic  support  for  pa-
tients  awaiting  heart  transplantation  with  improved  functional 
status and quality of life [4]. We subsequently decided to in-
sert  an  LVAD  as  a  bridge  treatment  for  left  ventricle 
function.
Since we used the extracorporeal type of VAD for this pa-
tient,  she  experienced  some  discomfort  due  to  limited 
mobility.  However,  the  patient  continued  receiving  LVAD 
support  for  15  days,  which  allowed  her  organ  function  to 
improve. A heart transplantation was performed after stabiliz-
ing  her  body  condition.  However,  after  the  heart  trans-
plantation,  wound  dehiscence  occurred.  Moreover,  due  to  the 
development of pneumonia, the patient needed long-term hos-
pital  care.
Currently,  many  patients  with  advanced  heart  failure  who 
do  not  respond  to  medical  treatment  are  waiting  for  heart 
transplantation;  however, donor  hearts are limited in  quantity. 
Moreover,  some  patients  can  die  of  multi-organ  failure  while 
they are waiting for heart donors. In this case, VAD applica-
t i o n  w a s  u s e f u l  a s  a  b r i d g i n g  treatment  before  heart  transp-
lantation.
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